You just read:

Roche and the pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for Multiple Sclerosis Treatment, OCREVUS® (ocrelizumab), for both RRMS and PPMS

News provided by

Roche Canada

Mar 19, 2019, 10:00 ET